PMID- 35978600
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220819
IS  - 2235-1795 (Print)
IS  - 1664-5553 (Electronic)
IS  - 1664-5553 (Linking)
VI  - 11
IP  - 4
DP  - 2022 Jul
TI  - Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial 
      Chemoembolization in Patients with Unresectable, Advanced Hepatocellular 
      Carcinoma: A Real-World, Multicenter, Retrospective Study.
PG  - 368-382
LID - 10.1159/000523849 [doi]
AB  - INTRODUCTION: Lenvatinib is the first-line treatment for advanced hepatocellular 
      carcinoma (HCC). We aimed to compare the clinical outcomes of lenvatinib plus 
      drug-eluting beads transarterial chemoembolization (DEB-TACE) versus lenvatinib 
      alone in real-world practice. METHODS: This retrospective analysis included 142 
      consecutive patients who received lenvatinib plus DEB-TACE and 69 patients who 
      received lenvatinib alone as first-line treatment from 15 Chinese academic 
      centers from November 2018 to November 2019. Overall survival (OS), 
      progression-free survival (PFS), objective response rate (ORR) were evaluated by 
      modified Response Evaluation Criteria in Solid Tumors criteria, and safety 
      profiles were compared between the two groups. RESULTS: The median OS and PFS 
      were significantly longer in the combined therapy group than in the monotherapy 
      group in whole cohort (median OS, 15.9 vs. 8.6 months, p = 0.0022; median PFS, 
      8.6 vs. 4.4 months, p < 0.001) and after propensity score matching analysis 
      (median OS, 13.8 vs. 7.8 months, p = 0.03; median PFS, 7.8 vs. 4.5 months, p = 
      0.009). Moreover, the treatment option was an independent prognostic factor for 
      OS and PFS with adjustment based upon baseline characteristics (adjusted hazard 
      ratio [HR]: 0.53, 95% confidence interval [CI]: 0.36-0.78, p = 0.001, and 
      adjusted HR: 0.42, 95% CI: 0.30-0.60, p < 0.001, respectively) and propensity 
      score (adjusted HR: 0.52, 95% CI: 0.36-0.76, p = 0.001, and adjusted HR: 0.46, 
      95% CI: 0.33-0.64, p < 0.001, respectively). Moreover, a greater ORR was observed 
      in the combined group (ORR: 46.48% vs. 13.05%, p < 0.001). Furthermore, the most 
      common adverse events (AEs) were elevated aspartate aminotransferase (54.9%) and 
      fatigue (46.4%) in the lenvatinib plus DEB-TACE group and lenvatinib group, 
      respectively. Most AEs were mild-to-moderate and manageable. CONCLUSIONS: With 
      well-tolerated safety, lenvatinib plus DEB-TACE was more effective than 
      lenvatinib monotherapy in improving OS, PFS, and ORR. Thus, it may be a promising 
      treatment for advanced HCC. Future prospective studies confirming these findings 
      are warranted.
CI  - Copyright (c) 2022 by The Author(s). Published by S. Karger AG, Basel.
FAU - Xia, Dongdong
AU  - Xia D
AD  - Department of Liver Diseases and Interventional Radiology, Digestive Diseases 
      Hospital, Xi'an International Medical Center Hospital, Northwest University, 
      Xi'an, China.
AD  - Department of Liver Disease and Digestive Interventional Radiology, National 
      Clinical Research Center for Digestive Disease and Xijing Hospital of Digestive 
      Diseases, Fourth Military Medical University, Xi'an, China.
FAU - Bai, Wei
AU  - Bai W
AD  - Department of Liver Diseases and Interventional Radiology, Digestive Diseases 
      Hospital, Xi'an International Medical Center Hospital, Northwest University, 
      Xi'an, China.
AD  - Department of Liver Disease and Digestive Interventional Radiology, National 
      Clinical Research Center for Digestive Disease and Xijing Hospital of Digestive 
      Diseases, Fourth Military Medical University, Xi'an, China.
FAU - Wang, Enxin
AU  - Wang E
AD  - Department of Liver Diseases and Interventional Radiology, Digestive Diseases 
      Hospital, Xi'an International Medical Center Hospital, Northwest University, 
      Xi'an, China.
AD  - Department of Medical Affairs, Air Force Hospital of Western Theater Command, 
      Chengdu, China.
FAU - Li, Jiaping
AU  - Li J
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Sun 
      Yat-sen University, Guangzhou, China.
FAU - Chen, Xiaoming
AU  - Chen X
AD  - Department of Interventional Radiology, Cancer Center, Guangdong Provincial 
      People's Hospital, Guangdong Provincial Academy of Medical Sciences, Guangzhou, 
      China.
FAU - Wang, Zhexuan
AU  - Wang Z
AD  - Department of Liver Disease and Digestive Interventional Radiology, National 
      Clinical Research Center for Digestive Disease and Xijing Hospital of Digestive 
      Diseases, Fourth Military Medical University, Xi'an, China.
FAU - Huang, Mingsheng
AU  - Huang M
AD  - Department of Interventional Radiology, The Third Affiliated Hospital of Sun 
      Yat-sen University, Guangzhou, China.
FAU - Huang, Ming
AU  - Huang M
AD  - Department of Minimally Invasive International Therapy, The Third Affiliated 
      Hospital of Kunming University, Tumor Hospital of Yunnan Province, Kunming, 
      China.
FAU - Sun, Junhui
AU  - Sun J
AD  - Department of Hepatobiliary and Pancreatic Interventional Cancer, The First 
      Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
FAU - Yang, Weizhu
AU  - Yang W
AD  - Department of Interventional Radiology, Fujian Medical University Union Hospital, 
      Fuzhou, China.
FAU - Lin, Zhengyu
AU  - Lin Z
AD  - Department of Interventional Radiology, First Affiliated Hospital of Fujian 
      Medical University, Fuzhou, China.
FAU - Wu, Jianbing
AU  - Wu J
AD  - Department of Oncology, The Second Affiliated Hospital of Nanchang University, 
      Nanchang, China.
FAU - Li, Zixiang
AU  - Li Z
AD  - Department of Interventional Radiology, The Affiliated Tumor Hospital of Xinjiang 
      Medical University, Urumqi, China.
FAU - Yang, Shufa
AU  - Yang S
AD  - Interventional Medical Center of the Affiliated Hospital of Qingdao University, 
      Qingdao, China.
FAU - Zhu, Xu
AU  - Zhu X
AD  - Department of Interventional Radiology, Peking University Cancer Hospital, 
      Beijing, China.
FAU - Chen, Zaizhong
AU  - Chen Z
AD  - Department of Interventional Radiology, Peking University Shenzhen Hospital, 
      Shenzhen, China.
FAU - Zhang, Yanfang
AU  - Zhang Y
AD  - Department of Interventional Radiology, Shenzhen People's Hospital, Shenzhen, 
      China.
FAU - Fan, Wenzhe
AU  - Fan W
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Sun 
      Yat-sen University, Guangzhou, China.
FAU - Mai, Qicong
AU  - Mai Q
AD  - Department of Interventional Radiology, Cancer Center, Guangdong Provincial 
      People's Hospital, Guangdong Provincial Academy of Medical Sciences, Guangzhou, 
      China.
FAU - Ding, Rong
AU  - Ding R
AD  - Department of Minimally Invasive International Therapy, The Third Affiliated 
      Hospital of Kunming University, Tumor Hospital of Yunnan Province, Kunming, 
      China.
FAU - Nie, Chunhui
AU  - Nie C
AD  - Department of Hepatobiliary and Pancreatic Interventional Cancer, The First 
      Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
FAU - Feng, Long
AU  - Feng L
AD  - Department of Oncology, The Second Affiliated Hospital of Nanchang University, 
      Nanchang, China.
FAU - Li, Xueda
AU  - Li X
AD  - Department of Interventional Radiology, The Affiliated Tumor Hospital of Xinjiang 
      Medical University, Urumqi, China.
FAU - Huang, Wukui
AU  - Huang W
AD  - Interventional Medical Center of the Affiliated Hospital of Qingdao University, 
      Qingdao, China.
FAU - Sun, Jun
AU  - Sun J
AD  - Department of Liver Disease and Digestive Interventional Radiology, National 
      Clinical Research Center for Digestive Disease and Xijing Hospital of Digestive 
      Diseases, Fourth Military Medical University, Xi'an, China.
FAU - Wang, Qiuhe
AU  - Wang Q
AD  - Department of Liver Disease and Digestive Interventional Radiology, National 
      Clinical Research Center for Digestive Disease and Xijing Hospital of Digestive 
      Diseases, Fourth Military Medical University, Xi'an, China.
FAU - Lv, Yong
AU  - Lv Y
AD  - Department of Liver Disease and Digestive Interventional Radiology, National 
      Clinical Research Center for Digestive Disease and Xijing Hospital of Digestive 
      Diseases, Fourth Military Medical University, Xi'an, China.
FAU - Li, Xiaomei
AU  - Li X
AD  - Department of Liver Diseases and Interventional Radiology, Digestive Diseases 
      Hospital, Xi'an International Medical Center Hospital, Northwest University, 
      Xi'an, China.
FAU - Luo, Bohan
AU  - Luo B
AD  - Department of Liver Diseases and Interventional Radiology, Digestive Diseases 
      Hospital, Xi'an International Medical Center Hospital, Northwest University, 
      Xi'an, China.
FAU - Wang, Zhengyu
AU  - Wang Z
AD  - Department of Liver Diseases and Interventional Radiology, Digestive Diseases 
      Hospital, Xi'an International Medical Center Hospital, Northwest University, 
      Xi'an, China.
FAU - Yuan, Jie
AU  - Yuan J
AD  - Department of Liver Diseases and Interventional Radiology, Digestive Diseases 
      Hospital, Xi'an International Medical Center Hospital, Northwest University, 
      Xi'an, China.
FAU - Guo, Wengang
AU  - Guo W
AD  - Department of Liver Diseases and Interventional Radiology, Digestive Diseases 
      Hospital, Xi'an International Medical Center Hospital, Northwest University, 
      Xi'an, China.
FAU - Li, Kai
AU  - Li K
AD  - Department of Liver Disease and Digestive Interventional Radiology, National 
      Clinical Research Center for Digestive Disease and Xijing Hospital of Digestive 
      Diseases, Fourth Military Medical University, Xi'an, China.
FAU - Li, Bing
AU  - Li B
AD  - Department of Liver Diseases and Interventional Radiology, Digestive Diseases 
      Hospital, Xi'an International Medical Center Hospital, Northwest University, 
      Xi'an, China.
FAU - Li, Ruijun
AU  - Li R
AD  - Department of Liver Diseases and Interventional Radiology, Digestive Diseases 
      Hospital, Xi'an International Medical Center Hospital, Northwest University, 
      Xi'an, China.
FAU - Yin, Zhanxin
AU  - Yin Z
AD  - Department of Liver Diseases and Interventional Radiology, Digestive Diseases 
      Hospital, Xi'an International Medical Center Hospital, Northwest University, 
      Xi'an, China.
FAU - Xia, Jielai
AU  - Xia J
AD  - Department of Health Statistics, Fourth Military Medical University, Xi'an, 
      China.
FAU - Han, Guohong
AU  - Han G
AD  - Department of Liver Diseases and Interventional Radiology, Digestive Diseases 
      Hospital, Xi'an International Medical Center Hospital, Northwest University, 
      Xi'an, China.
AD  - Department of Liver Disease and Digestive Interventional Radiology, National 
      Clinical Research Center for Digestive Disease and Xijing Hospital of Digestive 
      Diseases, Fourth Military Medical University, Xi'an, China.
LA  - eng
PT  - Journal Article
DEP - 20220309
PL  - Switzerland
TA  - Liver Cancer
JT  - Liver cancer
JID - 101597993
PMC - PMC9294948
OTO - NOTNLM
OT  - Drug-eluting beads transarterial chemoembolization
OT  - Efficacy
OT  - Hepatocellular carcinoma
OT  - Lenvatinib
OT  - Safety
EDAT- 2022/08/19 06:00
MHDA- 2022/08/19 06:01
PMCR- 2022/03/09
CRDT- 2022/08/18 02:03
PHST- 2021/10/24 00:00 [received]
PHST- 2022/02/25 00:00 [accepted]
PHST- 2022/08/18 02:03 [entrez]
PHST- 2022/08/19 06:00 [pubmed]
PHST- 2022/08/19 06:01 [medline]
PHST- 2022/03/09 00:00 [pmc-release]
AID - lic-0011-0368 [pii]
AID - 10.1159/000523849 [doi]
PST - epublish
SO  - Liver Cancer. 2022 Mar 9;11(4):368-382. doi: 10.1159/000523849. eCollection 2022 
      Jul.